Tan, Y. et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int. J. Oral Sci. 15 (1), 44 (2023).
Google Scholar
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71 (3), 209–249 (2021).
Google Scholar
Bankvall, M. et al. Common oral mucosal lesions. Den Nor. Tann Tid. 134 (2), 126–138 (2024).
Jagadeesan, D. et al. Comprehensive insights into oral squamous cell carcinoma: diagnosis, pathogenesis, and therapeutic advances. Pathol. Pract. 261, 155489 (2024).
Google Scholar
Peng, Z. et al. Application of radiomics and machine learning in head and neck cancers. Int. J. Biol. Sci. 17 (2), 475 (2021).
Google Scholar
Puttaraju, M. K. & Nitin, P. Conceptual model for progression of oral cancer-our perspective. Am. J. Cancer Res. 13 (8), 3650 (2023).
Google Scholar
Farah, C. S. Molecular, genomic and mutational landscape of oral leukoplakia. Oral Dis. 27 (4), 803–812 (2021).
Google Scholar
Dave, K., Ali, A. & Magalhaes, M. Increased expression of PD-1 and PD-L1 in oral lesions progressing to oral squamous cell carcinoma: A pilot study. Sci. Rep. 10 (1), 1–11 (2020).
Google Scholar
Caruntu A, Scheau C, Tampa M, Georgescu SR, Caruntu C, Tanase C. Complex Interaction among immune, inflammatory, and carcinogenic mechanisms in the head and neck squamous cell carcinoma. In: Best Practice in Health Care. Springer; 2021. p. 11–35.
Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20 (11), 651–668 (2020).
Google Scholar
Gao, A., Pan, X., Yang, X. & Lin, Z. Predictive factors in the treatment of oral squamous cell carcinoma using PD-1/PD-L1 inhibitors. Invest. New. Drugs. 39, 1132–1138 (2021).
Google Scholar
Roerden, M. & Spranger, S. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat. Rev. Immunol. 25 (5), 353–369 (2025).
Google Scholar
Mahamed, R., Monchusi, B., Penny, C. & Mirza, S. Cancer-derived exosomes: mediators of immune crosstalk and emerging targets for immunotherapy. Front. Immunol. 16, 1679934 (2025).
Google Scholar
Tavakoli, F., Sartakhti, J. S., Manshaei, M. H. & Basanta, D. Cancer immunoediting: A game theoretical approach. Silico Biol. 14 (1–2), 1–12 (2021).
Google Scholar
Tang, Q. et al. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. 13, 964442 (2022).
Google Scholar
Ai, L., Xu, A. & Xu, J. Roles of PD-1/PD-L1 pathway: signaling, cancer, and beyond. Regul. Cancer Immune Checkpoints Mol. Cell. Mech. Ther. ;33–59. (2020).
Lin, X. et al. Regulatory mechanisms of PD-1/PD-L1 in cancers. Mol. Cancer. 23 (1), 108 (2024).
Google Scholar
Banerjee, S. et al. Role of cytotoxic T cells and PD-1 immune checkpoint pathway in papillary thyroid carcinoma. Front. Endocrinol. (Lausanne). 13, 931647 (2022).
Google Scholar
Singh, S. et al. Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy. 3 Biotech. 13 (12), 411 (2023).
Google Scholar
Han, Y., Liu, D., Li, L. & PD-1 /PD-L1 pathway: current researches in cancer [Internet]. Vol. 10, American journal of cancer research. Pathology Department of Dalian Medical University Liaoning 116044, China.; pp. 727–42. Available from: http://europepmc.org/abstract/MED/32266087 (2020).
Helmy, D. O., Khattab, F., Hegazy, A. E. & Sabry, R. M. Immunohistochemical expression of immune check point protein PDL-1 in hepatocellular carcinoma denotes its prognostic significance and association with survival. J. Immunoass. Immunochem. 44 (3), 213–228 (2023).
Google Scholar
Lenouvel, D. et al. Clinicopathological and prognostic significance of PD‐L1 in oral cancer: A preliminary retrospective immunohistochemistry study. Oral Dis. 27 (2), 173–182 (2021).
Google Scholar
Weber, M. et al. Prognostic significance of PD‐L2 expression in patients with oral squamous cell carcinoma—A comparison to the PD‐L1 expression profile. Cancer Med. 8 (3), 1124–1134 (2019).
Google Scholar
Muller, S. & Tilakaratne, W. M. Update from the 5th edition of the World Health Organization classification of head and neck tumors: tumours of the oral cavity and mobile tongue. Head Neck Pathol. 16 (1), 54–62 (2022).
Google Scholar
Chen, S. W. et al. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance. Int. J. Biol. Markers. 34 (4), 398–405 (2019).
Google Scholar
Maruse, Y. et al. Significant association of increased PD-L1 and PD-1 expression with nodal metastasis and a poor prognosis in oral squamous cell carcinoma. Int. J. Oral Maxillofac. Surg. 47 (7), 836–845 (2018).
Google Scholar
Blatt, S. et al. Differences in PD-L1 Expression between oral and oropharyngeal squamous cell carcinoma. PLoS One. 17 (5), e0269136 (2022).
Google Scholar
Geum, D. H. et al. PD-L1 expression correlated with clinicopathological factors and Akt/Stat3 pathway in oral SCC. Life 12 (2), 238 (2022).
Google Scholar
Wahbi, H. S. & Al Manadili, A. The expression of PDL-1 and PD1 in the microenvironment of oral squamous cell carcinoma. Asian Pac. J. cancer Prev. APJCP. 25 (10), 3471 (2024).
Google Scholar
Mneimneh, W. S. et al. Clinicopathologic characteristics of young patients with oral squamous cell carcinoma. Head Neck Pathol. ;1–10. (2021).
Saeed, S. et al. Comparison of PD-L1 Expression in Oral Squamous Cell Carcinoma and Premalignant Lesions of Oral Cavity. Asian Pac. J. Cancer Prev. APJCP. 23 (12), 4039 (2022).
Google Scholar
Elmetwaly, M. M. F. et al. Morbidity Profile of Cases Attended Oncology Center of Mansoura University (OCMU), Egypt: A Cross-Sectional Study. Osong Public. Heal Res. Perspect. 10 (3), 177 (2019).
Google Scholar
Wolfer, S. et al. Gender and risk‐taking behaviors influence the clinical presentation of oral squamous cell carcinoma. Clin. Exp. Dent. Res. 8 (1), 141–151 (2022).
Google Scholar
Greeshma, L. R., Joseph, A. P., Sivakumar, T. T., Raghavan Pillai, V. & Vijayakumar, G. Correlation of PD-1 and PD-L1 expression in oral leukoplakia and oral squamous cell carcinoma: an immunohistochemical study. Sci. Rep. 13 (1), 21698 (2023).
Google Scholar
Tealab, S. H., Sedhom, N. F. H., Hassouna, A., Gouda, I. & Ismail, H. Prevalence of human papilloma virus in oropharyngeal, tongue and lip squamous cell carcinoma: an experience from the Egyptian National Cancer Institute. J. Investig Med. 67 (7), 1061–1066 (2019).
Google Scholar
Janović, A., Bracanović, Đ., Antić, S. & Marković-Vasiljković, B. Demographic and imaging features of oral squamous cell cancer in Serbia: a retrospective cross-sectional study. BMC Oral Health. 24 (1), 141 (2024).
Google Scholar
Lee, Y. C. et al. Characteristics and outcome differences in male and female oral cavity cancer patients in Taiwan. Med. (Baltim). ;100(44). (2021).
Louredo, B. V. R. et al. Epidemiology and survival outcomes of lip, oral cavity, and oropharyngeal squamous cell carcinoma in a southeast Brazilian population. Med. Oral Patol. Oral Cir. Bucal. 27 (3), e274 (2022).
Google Scholar
Gondivkar, S. M. et al. Oral and general health-related quality of life in oral squamous cell carcinoma patients-comparative analysis of different treatment regims. J. Oral Biol. Craniofac. Res. 11 (2), 125–131 (2021).
Google Scholar
Khawaja, S. N., Jamshed, A. & Hussain, R. T. Prevalence of pain in oral cancer: A retrospective study. Oral Dis. 27 (7), 1806–1812 (2021).
Google Scholar
Albano, D. et al. Oral Squamous Cell Carcinoma: Features and Medico-Legal Implications of Diagnostic Omission. Case Rep. Dent. 2024 (1), 2578271 (2024).
Google Scholar
Yasin, M. M., Abbas, Z. & Hafeez, A. Correlation of histopathological patterns of OSCC patients with tumor site and habits. BMC Oral Health. 22 (1), 305 (2022).
Google Scholar
Chen, J., Zou, D., Zan, H., Li, X. & Kim, H. J. Evaluating differentiation grade as a guide for decision-making in elective neck dissection for early-stage oral squamous cell carcinoma: a population-based cohort study. Transl Cancer Res. ;15(1). (2026).
Fatima, J. et al. Comprehensive analysis of oral squamous cell carcinomas: clinical, epidemiological, and histopathological insights with a focus on prognostic factors and survival time. Cureus ;16(2). (2024).
Kannan, N. et al. Immune evasion mechanisms and cutting-edge therapeutic strategies of PD-L1 pathway in oral squamous cell carcinoma: an umbrella review. Explor. Immunol. 5, 1003228 (2025).
Google Scholar
Hu, J., Li, Y., Lian, B., Mao, Y. & Zhao, L. Mechanism and role of regulated cell death in tumor immunity and immunotherapy. Cancer Commun. 45 (11), 1456–1495 (2025).
Google Scholar
Zhang, Y. C., Zhang, Y. T., Wang, Y., Zhao, Y. & He, L. J. What role does PDL1 play in EMT changes in tumors and fibrosis? Front. Immunol. 14, 1226038 (2023).
Google Scholar
Kim, T. K., Vandsemb, E. N., Herbst, R. S. & Chen, L. Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities. Nat. Rev. Drug Discov. 21 (7), 529–540 (2022).
Google Scholar
Heeren, A. M. et al. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. J. Immunother Cancer. 9 (10), e003623 (2021).
Google Scholar
Okada, S. et al. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. Surg. Oncol. 27 (2), 259–265 (2018).
Google Scholar
de Vicente, J. C. et al. PD-L1 expression in tumor cells is an independent unfavorable prognostic factor in oral squamous cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 28 (3), 546–554 (2019).
Google Scholar
Parvez, A. et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment. Front. Immunol. 14, 1296341 (2023).
Google Scholar
Kawczak, P., Feszak, I. J. & Bączek, T. Comparative Mechanistic Insights and Therapeutic Potential of Pembrolizumab, Durvalumab, and Ipilimumab as Immune Checkpoint Inhibitors in the Targeted Management of Oral and Head and Neck Squamous Cell Carcinoma. Cancers (Basel). 17 (17), 2805 (2025).
Google Scholar
Javed, S. A., Najmi, A., Ahsan, W., Zoghebi, K. & Targeting PD-1/PD-L-1 immune checkpoint inhibition for cancer immunotherapy: success and challenges. Front. Immunol. 15, 1383456 (2024).
Google Scholar
Ilié, M. et al. Lack of correlation between MET and PD-L1 expression in non-small cell lung cancer revealed by comparative study of matched biopsies and surgical resection samples. Lung Cancer. 181, 107230 (2023).
Google Scholar
Bernadett, L. et al. No Correlation between PD-L1 and NIS Expression in Lymph Node Metastatic Papillary Thyroid Carcinoma. Diagnostics 14 (17), 1858 (2024).
Google Scholar
Hanroongsri, J., Amornphimoltham, P., Younis, R. H. & Chaisuparat, R. Expression of PD-L1 and p-RPS6 in epithelial dysplasia and squamous cell carcinoma of the oral cavity. Front. Oral Heal. 5, 1337582 (2024).
Google Scholar
Vainer, G. W. et al. Unraveling the complexity of PD-L1 assays: a descriptive review of the methodology, scoring, and practical implications. Front. Oncol. 15, 1581275 (2025).
Google Scholar
Kamiya, S. et al. Association between PD-L1 expression and lymph node metastasis in cutaneous squamous cell carcinoma. Asia-Pacific J. Clin. Oncol. 16 (2), e108–e112 (2020).
Google Scholar
